홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.1
  1. 홈
  2. /화합물

칸나비다이올

Cannabidiol

HCID 644019
새 반응
인쇄

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
13956-29-1
표준 SMILES
C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O
InChIKey
QHMBSVQNZZTUGM-ZWKOTPCHSA-N
분자식
C21H30O2
평균 분자량
314.5 g/mol

개요

Cannabidiol is an cannabinoid that is cyclohexene which is substituted by a methyl group at position 1, a 2,6-dihydroxy-4-pentylphenyl group at position 3, and a prop-1-en-2-yl group at position 4. It has a role as an antimicrobial agent and a plant metabolite. It is a member of resorcinols, a phytocannabinoid and an olefinic compound.

이름 및 식별자

우선 이름
Cannabidiol
IUPAC
2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
현지명
칸나비다이올
영어명
CANNABIDIOL
분자식
C21H30O2
분자량
314.46

이름 및 동의어

cannabidiol13956-29-1(-)-Cannabidiol(-)-trans-CannabidiolEpidiolexGWP42003-Pdelta1(2)-trans-CannabidiolCARDIOLRXcannabidiolum(-)-trans-2-p-Mentha-1,8-dien-3-yl-5-pentylresorcinol19GBJ60SN5CHEBI:69478
이름 더 보기
칸나비다이올CBDCBD IsolateCBD oilcannabidiol (CBD)CBD isolate powder2-[(1R,6R)-3-METHYL-6-(1-METHYLETHENYL)-2-CYCLOHEXEN-1-YL]-5-PENTYL-1,3-BENZENEDIOLC07578CBD crystal
DTXSID00871959BTX-1204BTX-1503GWP42003GWP-42003-PGWP-42003(1'R,2'R)-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydrobiphenyl-2,6-diol1,3-Benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1R-trans)-

데이터베이스 식별자

CAS
13956-29-1、3556-78-3
PubChem CID
644019
DTXSID
DTXSID00871959

물성

구조 계산 물성보충 중

XLogP
6.5
극성 표면적
40.5 Ų
수소 결합 공여자 수
2
수소 결합 수용자 수
2
회전 가능 결합 수
6
무거운 원자 수
23
형식 전하
0
복잡도
414

실험 및 물리화학적 성질

Chemical ClassesStimulant
DrugsDEA NFLIS-Drug Category -> Cannabinoids
LipidsPolyketides [PK] -> Aromatic polyketides [PK13] -> Other aromatic polyketides [PK1312]
Dietary Ingredients · 2건

Cannabidiol (CBD)

CBD (cannabidiol)

Human Drugs · 5건

Breast feeding; Lactation; Milk, Human; Anticonvulsants; Cannabinoids

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine (Orphan designations)

FDA approved drugs -> Active ingredient

Pharmaceuticals

Endocrine DisruptorsPotential endocrine disrupting compound

물리화학적 성질

녹는점
62 · 62-63°C
끓는 점
2 · bp2 187-190° (bath temp 220°); bp0.001 130°
밀도
440 · d440 1.040
굴절률
20 · nD20 1.5404
인화점
11 °C · 11 °C
저장 조건

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Warning

H302 (41.7%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P261, P264, P270, P271, P280, P301+P317, P304+P340, P317, P318, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 36 reports by companies from 14 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Regulatory InformationCannabidiol: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Hazard Classes and CategoriesAcute Tox. 4 (41.7%)

독성 정보

Hepatotoxicity · 1건

In prelicensure studies, serum aminotransferase elevations arose during cannabidiol therapy for epilepsy in 34% to 47% of patients compared to 18% of controls who were receiving other anticonvulsant medications. Elevations above 3 times ULN occurred in 13% of cannabidiol treated compared to 1% on placebo. ALT and AST elevations were more frequent with higher doses and were particularly common (and sometimes delayed) in patients who were receiving valproate and clobazam. The aminotransferase elevations typically arose within the first two months of treatment and were transient, mild-to-moderate in severity, and not associated with symptoms or jaundice. There have been no convincing reports of clinically apparent liver injury with jaundice attributable to prescription forms of cannabidiol, but it has had very limited general use.

Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Cannabidiol

Ambiguous-DILI-concern

화학 및 산업

약리 정보

ATC Code · 2건

N - Nervous system

QN - Nervous system

Pharmacodynamics · 1건

Although the exact mechanism and magnitude of effects of THC and CBD are not fully understood, CBD has been shown to have analgesic, anticonvulsant, muscle relaxant, anxiolytic, neuroprotective, anti-oxidant, and anti-psychotic activity. This wide variety of effects is likely due to it's complex pharmacological mechanisms. In addition to binding to CB1 and CB2 receptors of the endocannabinoid system, there is evidence that CBD activates 5-HT1A serotonergic and TRPV1–2 vanilloid receptors, antagonizes alpha-1 adrenergic and µ-opioid receptors, inhibits synaptosomal uptake of noradrenaline, dopamine, serotonin and gaminobutyric acid and cellular uptake of anandamide, acts on mitochondria Ca2 stores, blocks low-voltage-activated (T-type) Ca2 channels, stimulates activity of the inhibitory glycine-receptor, and inhibits activity of fatty amide hydrolase (FAAH).

Mechanism of Action · 1건

The exact mechanism of action of CBD and THC is not currently fully understood. However, it is known that CBD acts on cannabinoid (CB) receptors of the endocannabinoid system, which are found in numerous areas of the body, including the peripheral and central nervous systems, including the brain. The endocannabinoid system regulates many physiological responses of the body including pain, memory, appetite, and mood. More specifically, CB1 receptors can be found within the pain pathways of the brain and spinal cord where they may affect CBD-induced analgesia and anxiolysis, and CB2 receptors have an effect on immune cells, where they may affect CBD-induced anti-inflammatory processes. CBD has been shown to act as a negative allosteric modulator of the cannabinoid CB1 receptor, the most abundant G-Protein Coupled Receptor (GPCR) in the body. Allosteric regulation of a receptor is achieved through the modulation of the activity of a receptor on a functionally distinct site from the agonist or antagonist binding site. The negative allosteric modulatory effects of CBD are therapeutically important as direct agonists are limited by their psychomimetic effects while direct antagonists are limited by their depressant effects.

Biological Half-LifeThe CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.

관련 반응

5건
반응 기록 만들기
HRID 426094 반응식
HRID 426094반응물로uspto-grants-2012_01
HRID 426096 반응식
HRID 426096반응물로uspto-grants-2012_01
HRID 2067148 반응식
HRID 2067148반응물로uspto-grants-2012_10
HRID 2243453 반응식
HRID 2243453반응물로uspto-grants-2010_03
HRID 2243455 반응식
HRID 2243455반응물로uspto-grants-2010_03

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
ChEMBL
CHEMBL190461
ChEBI
CHEBI:69478
UNII
19GBJ60SN5、QJ36T2J3TS
EC Number
689-176-3、952-348-6
Nikkaji
J10.356J
2 · 2-8°C
용해도
75 mM · Soluble to 75 mM in ethanol and to 75 mM in DMSO
물리적 상태
가루
색상
하얀색
주요 응용
제약
화장품 원료 기능
피지 억제피부 보호항산화제피부 컨디셔닝
InChI
1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18/m0/s1
InChIKey
QHMBSVQNZZTUGM-ZWKOTPCHSA-N
LogP
6.6 · 6.600 (est)
EPA
1 · 1,3-Benzenediol, 2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl- (13956-29-1)

화학적 성질

Off-White Solid

3

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

안전 데이터

wgk
1
rtecs
VH1600000
ridadr
UN 1230 3/PG 2
risk_code
11-23/24/25-39/23/24/25
hazard_code
F,T
safety_code
36/37-45-16-7
Metabolism/Metabolites · 1건

THC and CBD are metabolized in the liver by a number of cytochrome P450 isoenzymes, including CYP2C9, CYP2C19, CYP2D6 and CYP3A4. They may be stored for as long as four weeks in the fatty tissues from which they are slowly released at sub-therapeutic levels back into the blood stream and metabolized via the renal and biliary systems. The main primary metabolite of CBD is 7-hydroxy-cannabidiol.

FDA Pharmacological Classification · 6건

19GBJ60SN5

CANNABIDIOL

Chemical Structure [CS] - Cannabinoids

Mechanisms of Action [MoA] - Cytochrome P450 2C8 Inhibitors

Mechanisms of Action [MoA] - Cytochrome P450 2C9 Inhibitors

Mechanisms of Action [MoA] - Cytochrome P450 2C19 Inhibitors

MeSH Pharmacological ClassificationDrugs used to prevent SEIZURES or reduce their severity.
Absorption, Distribution and Excretion · 3건

Following a single buccal administration, maximum plasma concentrations of both CBD and THC typically occur within two to four hours. When administered buccally, blood levels of THC and other cannabinoids are lower compared with inhalation of smoked cannabis. The resultant concentrations in the blood are lower than those obtained by inhaling the same dose because absorption is slower, redistribution into fatty tissues is rapid and additionally some of the THC undergoes hepatic first pass metabolism to 11-OH-THC, a psycho-active metabolite. The CBD component of sublingual Sativex was found to have a Tmax of 1.63hr and a Cmax of 2.50ng/mL, while buccal Sativex was found to have a Tmax of 2.80hr and a Cmax of 3.02ng/mL.

Elimination from plasma is bi-exponential with an initial half-life of one to two hours. The terminal elimination half-lives are of the order of 24 to 36 hours or longer. Sativex is excreted in the urine and faeces.

Cannabinoids are distributed throughout the body; they are highly lipid soluble and accumulate in fatty tissue. The release of cannabinoids from fatty tissue is responsible for the prolonged terminal elimination half-life.

용도 및 제조

Use ClassificationPharmaceuticals
응용 분야 · 2건

용도칸나비디올은 만성 통증을 가진 일부 사람들에 의해 사용된다. CBD는 통증, 염증 및 다양한 건강 상태와 관련된 전반적인 불편함을 줄일 수 있다. CBD는 cannabinoid의 한 유형으로, 마리화나와 대마 식물에서 자연적으로 발견되는 화학 물질이다. THC 라 불리는 다른 종류의 카나비노이드에 의해 유발되는 대마초와 관련된 환각 작용을 유발하지 않는다. 칸나비디올(Cannabidiol,CBD)은 만성 통증이 있고 오피오이드 와 같은 더 위험하고 습관성 약물에 의존하는 사람들에게 대안을 제시 할 수 있다 . 그러나 CBD 오일의 통증 완화 효과를 검증하기 위해서는 더 많은 연구가 필요하다.

용도Major non-psychoactive constituent of Cannabis. Exhibits multiple bioactivities including anticonvulsant, anxiolytic and anti-inflammatory effects. The (+)-isomers were more active than the (-)-isomers.

상·하류 제품 정보

하류 제품

테트라히드로칸나비놀

추가 설명

정의ChEBI: An cannabinoid that is cyclohexene which is substituted by a methyl group at position 1, a 2,6-dihydroxy-4-pentylphenyl group at position 3, and a prop-1-en-2-yl group at position 4.